Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

LA JOLLA, Calif., March 26 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced financial results for the fourth quarter and year ended December 31, 2007. For the full year 2007, the Company posted revenue of $9.9 million and a net loss of $23.4 million. Cash and cash equivalents totaled $32.5 million at December 31, 2007.

"We made meaningful progress in our three clinical development programs in 2007," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "Particularly noteworthy was the successful completion of our Phase IIb clinical trial that demonstrated that tezampanel relieved migraine pain at a dose that is safe and well-tolerated. We look forward to an End of Phase II meeting with the FDA to discuss advancing tezampanel into Phase III. In 2008, we are continuing to build a strong clinical platform for our other product candidates: NGX426, our oral glutamate receptor antagonist, and NGX267, our lead M1 agonist, that is currently in a Phase II trial for xerostomia secondary to Sjogren's syndrome."

2007 Highlights:

-- Tezampanel met the primary endpoint at the 40 mg dose in a 306-patient,

Phase IIb clinical trial for the treatment of a single, acute migraine

attack. This is the sixth Phase II trial in which tezampanel has been

shown to have analgesic activity and the second placebo-controlled

trial to establish efficacy for tezampanel as a treatment for acute

migraine. TorreyPines intends to hold an End of Phase II meeting with

the U.S. Food and Drug Administration (FDA) in the second half of 2008

to discuss the scope of a Phase III program with tezampanel for the

treatment o
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ... Biotech Outlook 2015: New Therapy Ventures Pave the Way ... All biotech companies - Gilead (GILD), Amgen (AMGN), ... have given a positive return and hence increased the ... to select therapy/niche indication where the high treatment cost ...
(Date:3/5/2015)... 05, 2015 RMI ... chronic orthopedic conditions such as meniscal tears, ACL ... and joint pain due to degenerative conditions like ... orthopedic surgeries to promote better post-surgical outcomes. , ... nearly pain-free bone marrow harvesting with two complimentary ...
(Date:3/4/2015)... 2015  Brooklyn residents now have a new place ... and injuries. Nunzio Saulle , M.D., a board-certified ... his NJS Physical Medicine and Rehabilitation (PM&R) practice in ... 5, 2015. Health Plus Management, LLC is managing the ... 1178 Flatbush Avenue. This new PM&R practice will treat ...
(Date:3/4/2015)... March 4, 2015 /CNW/ - Resverlogix Corp. (TSX:RVX) ... completed a collaborative research program with Emerald ... Fast Collective Evolution Technology (FACET), Emerald Logic ... measurements obtained from each of 798 patients ... clinical trials ASSERT, SUSTAIN and ASSURE. The ...
Breaking Biology Technology:Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 2Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 3Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program 4
... 13 Millennium,Pharmaceuticals, Inc. (Nasdaq: MLNM ) ... Global Pharmaceutical, Biotech and Medtech Conference,will be webcast ... Investors section,of the Company,s website, http://www.millennium.com . ... presentation will include an overview of the Company, ...
... Cephalon, Inc. (Nasdaq:,CEPH) today communicated with ... dosing and administration for FENTORA(R),(fentanyl buccal tablet) ... the medical community to reinforce the appropriate ... letter, issued in collaboration with the U.S. ...
... Technology Symposium Brings Together Thought Leaders,in Life Sciences ... Practices, OOSTERHOUT, Netherlands, Sept. 13 Luminex,Corporation ... multiplexed solutions,today announced the agenda for Planet xMAP ... The two-day event will be,held 2-3 October at ...
Cached Biology Technology:Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation 2Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 2Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 3Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 4Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA 5Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium 2Luminex Corporation Hosts the Fifth Annual Planet xMAP Europe 2007 Symposium 3
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
(Date:2/5/2015)... 27, 2015   Marvin Test Solutions ... innovative test solutions for military, aerospace, and ... its TS-323 GENASYS Test Platform ... GENASYS is a high-performance PXI-based system designed ... that require performance functional testing. GENASYS features ...
(Date:2/5/2015)... 2015  It is gratifying to see that the ... genomic science as a means to better understand human ... I was honored to participate in today,s White House ... Since the 1980s my teams have ... first sequenced genome of a free living organism, the ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... clinical study, researchers administered a new method for treating ... be worn like a band-aid. The applicator delivers low-frequency, ... significantly accelerate healing in five patients with venous ulcers. ... malfunction, causing blood to pool in the leg instead ...
... Calif.) Chanel, UC Santa Barbara,s corpse flower, has finally ... a cross between rotting flesh and Limburger cheese. "It,s disgusting," ... pretty nasty." Other visitors said Chanel smelled like "French ... a computer technician in the Life Science Computing Group at ...
... on a fatal case of potato poisoning: James B. Matheney ... bushels of tubers, which had turned green due to sunlight ... family -- wife, two daughters and four sons -- showed ... didn,t eat the potatoes, and a breast-fed baby boy. His ...
Cached Biology News:Ultrasound patch heals venous ulcers in human trial 2Ultrasound patch heals venous ulcers in human trial 3Ultrasound patch heals venous ulcers in human trial 4Chanel, UCSB's corpse flower, blooms and causes a big stink 2Chanel, UCSB's corpse flower, blooms and causes a big stink 3The pathway to potato poisons 2
... high quality whole genome sequencing service. Our ... allow even the smallest of laboratories to ... features which set our whole genome sequencing ... strategies, proprietary assembly software, rapid project turnaround ...
Sequencing and primer design rolled into one. Just give us your clone and a reference sequence, and we'll do the rest. Single-strand or double-strand coverage. Guaranteed results....
...
... Mynox is the first biological ... killing them, and not just ... the only anti-mycoplasma agent that ... virus stocks directly. The cytotoxicity ...
Biology Products: